StreetInsider.com  Aug 12  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Akorn+%28AKRX%29+Announces+Completion+of+VPI+Holdings+Acquisition/9743788.html for the full story.
TheStreet.com  Aug 8  Comment 
NEW YORK (TheStreet) -- A San Diego-based biopharmaceutical company is gaining international attention for an experimental Ebola treatment that just saved two lives. Mapp Biopharmaceutical is that company. Although it might sound like it employs...
SeekingAlpha  Aug 5  Comment 
Akorn, Inc. (NASDAQ:AKRX) Q2 2014 Earnings Conference Call August 5, 2014 10:00 AM ET Executives Raj Rai - CEO Tim Dick - CFO Analysts Randall Stanicky - RBC Capital Markets Traver Davis - Piper Jaffray David Krempa -...
TheStreet.com  Aug 5  Comment 
NEW YORK (TheStreet) -- Shares of Akorn Inc.  are up 4.86% to $36 in pre-market trade after the pharmaceutical company won U.S. antitrust approval to buy specialty prescription drug company VersaPharm on condition it sell its rights to a...
Reuters  Aug 4  Comment 
Pharmaceutical company Akorn Inc has won U.S. antitrust approval to buy specialty prescription drug company VersaPharm Inc on condition it sell its rights to a generic...
StreetInsider.com  Aug 4  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Akorn+%28AKRX%29+Agrees+to+Settlement+with+FTC+in+Proposed+Acquisiton+of+VersaPharm/9717477.html for the full story.
Benzinga  Jul 1  Comment 
Shares of Akorn (NASDAQ: AKRX) were up nearly 10 percent Tuesday around $36.50 following the release of a Needham note in which the price target for the company was raised from $30 to $40. The note cited a "game changing" effect if Akorn...
Benzinga  Jun 30  Comment 
MannKind (NASDAQ: MNKD) shares reached a new 52-week high of $11.15 following the Friday's conditional FDA approval for Afrezzaa. GW Pharmaceuticals plc (NASDAQ: GWPH) reached a new 52-week high of $104.343 as Piper Jaffray raised the price...
Benzinga  Jun 20  Comment 
Akorn (NASDAQ: AKRX) sold its branded drug unit for $41 million and saw its shares gain nearly four percent Friday morning. The unit, ECR Pharmaceuticals, went to Valeant Pharmaceuticals (NYSE: VRX) for a combination of $41 million cash and...
StreetInsider.com  Jun 20  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Akorn+%28AKRX%29+Divests+ECR+Pharma+Unit+in+%2441M+Deal+with+Valeant+%28VRX%29/9601083.html for the full story.

You may also be interested in articles related to Akorn (AKRX):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki